CeriBell, Inc. (NASDAQ:CBLL) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of CeriBell, Inc. (NASDAQ:CBLL) have earned a consensus rating of “Moderate Buy” from the seven analysts that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, four have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $22.40.

Several analysts have recently issued reports on the stock. Canaccord Genuity Group boosted their price objective on shares of CeriBell from $25.00 to $26.00 and gave the company a “buy” rating in a research note on Tuesday, August 11th. BTIG Research upped their price target on CeriBell from $28.00 to $30.00 and gave the stock a “buy” rating in a research note on Tuesday, August 18th. Weiss Ratings upgraded CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 13th. Finally, Barclays raised shares of CeriBell to a “neutral” rating in a research report on Tuesday, August 18th.

Insider Buying and Selling

In related news, Director Joseph Michael Taylor sold 13,095 shares of the company’s stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $23.40, for a total transaction of $306,423.00. Following the completion of the sale, the director directly owned 48,478 shares of the company’s stock, valued at approximately $1,134,385.20. This represents a 21.27% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Scott Blumberg sold 33,512 shares of the stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $25.03, for a total value of $838,805.36. Following the completion of the sale, the chief financial officer owned 148,121 shares of the company’s stock, valued at approximately $3,707,468.63. This represents a 18.45% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 369,286 shares of company stock valued at $7,718,927. 17.70% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On CeriBell

Several hedge funds have recently modified their holdings of the stock. BlackRock Inc. purchased a new position in CeriBell in the 2nd quarter worth approximately $37,657,000. Vanguard Group Inc. lifted its position in shares of CeriBell by 11.1% during the third quarter. Vanguard Group Inc. now owns 1,473,856 shares of the company’s stock worth $16,935,000 after purchasing an additional 147,013 shares in the last quarter. KCM Capital Inc boosted its stake in shares of CeriBell by 40.0% in the first quarter. KCM Capital Inc now owns 1,400,000 shares of the company’s stock valued at $25,662,000 after purchasing an additional 400,000 shares during the period. Yu Fan grew its holdings in CeriBell by 10.7% during the 2nd quarter. Yu Fan now owns 1,353,166 shares of the company’s stock valued at $25,345,000 after purchasing an additional 130,964 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its holdings in CeriBell by 1,945.9% during the 4th quarter. Bank of New York Mellon Corp now owns 1,221,927 shares of the company’s stock valued at $26,797,000 after purchasing an additional 1,162,200 shares in the last quarter.

CeriBell Trading Down 0.4%

Shares of NASDAQ CBLL traded down $0.09 on Monday, reaching $24.11. 13,902 shares of the company traded hands, compared to its average volume of 344,402. The stock has a market capitalization of $925.53 million, a PE ratio of -13.70 and a beta of 0.81. CeriBell has a fifty-two week low of $10.85 and a fifty-two week high of $25.33. The company has a current ratio of 9.18, a quick ratio of 8.79 and a debt-to-equity ratio of 0.16. The company has a 50 day moving average of $19.54 and a 200 day moving average of $19.22.

CeriBell (NASDAQ:CBLL) last released its earnings results on Monday, August 10th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.04). CeriBell had a negative net margin of 64.73% and a negative return on equity of 44.85%. The company had revenue of $28.10 million during the quarter, compared to analysts’ expectations of $27.28 million. On average, equities research analysts forecast that CeriBell will post -1.96 earnings per share for the current fiscal year.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.